Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC001 in advanced solid tumors
NCT06508307Phase 1Recruiting
- Sponsor
- Gongchu Biotechnology
- Start
- Apr 2023
- Primary completion
- Jan 2026
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC001 oncolytic vaccinia virus in solid tumor (advanced stage), sponsored by Gongchu Biotechnology. Primary endpoints: Safety and Tolerability (DLT, MTD, MFD) at 28 days and Maximal Tolerable Dose at 28 days. Started Apr 2023; status: recruiting.
02
Drugs
GC001 oncolytic vaccinia virus
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06508307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508307.